B.Riley cut its price target on Cue Biopharma to $25 from $83 while keeping a Buy rating, citing financing concerns following the company's third-quarter 2026 update. The stock trades at $2.83, down 84.83% over the past week, with a market cap of $20.56 million.
B.Riley said the approximately 75% sell-off was excessive given that clinical efficacy results for the lead program CUE-221 remain unchanged. The drug showed a 60% rate of HSS7=0 at 4 mg/kg at week 28, compared with 24% for Roche and Novartis's Xolair and 11% for placebo.
The firm noted the week 28 benefit persisted without clinically meaningful drug exposure and that predose free IgE continues to decline past PK steady state. 91% of 4 mg/kg patients showed suppression below quantification at week 1, including those above the Xolair food allergy dosing table.
Subcutaneous bioavailability of approximately 50% means 4 mg/kg SC approximates the 2 mg/kg IV Phase 1 cohort, B.Riley said. With safety established through 10 mg/kg and no neutralizing antibodies, the firm said this represents the exposure floor at which differentiation emerged.
B.Riley said the multi-year financing path is the largest driver of its price target cut. The firm noted the trade-off involves time and capital, as dose-ranging work could either precede or result in a larger Phase 3 multi-arm trial design.
InvestingPro analysis suggests the stock remains undervalued at current levels and appears on the platform's most undervalued stocks list.